Stay updated on Ad-p53+Xeloda/Anti-PD-1 Safety/Efficacy in Liver Metastases Clinical Trial

Sign up to get notified when there's something new on the Ad-p53+Xeloda/Anti-PD-1 Safety/Efficacy in Liver Metastases Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ad-p53+Xeloda/Anti-PD-1 Safety/Efficacy in Liver Metastases Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a change in the Maximum Tolerated Dose (MTD) for intra-arterial infusions in a Phase 1/2 study evaluating Ad-p53 in combination with capecitabine or pembrolizumab for patients with liver metastases and recurrent head and neck squamous cell carcinoma.
    Difference
    0.1%
    Check dated 2024-06-06T14:45:15.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying requirements such as age, consent, health conditions, and prior treatments. This change provides more comprehensive information on who can participate in the study.
    Difference
    41%
    Check dated 2024-05-22T21:26:27.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:26:41.000Z thumbnail image

Stay in the know with updates to Ad-p53+Xeloda/Anti-PD-1 Safety/Efficacy in Liver Metastases Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ad-p53+Xeloda/Anti-PD-1 Safety/Efficacy in Liver Metastases Clinical Trial page.